SEC Form 4 Filing for Acrivon Therapeutics, Inc.

Derek DiRocco, a director at Acrivon Therapeutics, Inc. (ACRV), acquired 9,366 shares of Common Stock on May 18, 2026. This acquisition was made through restricted stock units (RSUs) with a transaction price of $0.00 per share. The RSUs are set to vest in full on May 18, 2027, contingent upon DiRocco's continued service. It is noted that these RSUs are held for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., and DiRocco disclaims beneficial ownership as the shares received upon settlement will offset advisory fees owed to RA Capital Management, L.P. Following this transaction, DiRocco directly owns 9,366 shares.